Humanigen, Inc. (HGEN) |
|
0.137 0.002 (1.56%)
|
03-24 16:00 |
|
Open: |
0.1369 |
Pre. Close: |
0.1349 |
|
High:
|
0.1391 |
Low:
|
0.1311 |
|
Volume:
|
317,038 |
Market Cap:
|
16(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:26:42 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 0.17  One year: 0.19 |
| Support: |
Support1: 0.1 Support2: 0.09 |
| Resistance: |
Resistance1: 0.14 Resistance2: 0.17 |
| Pivot: |
0.14 |
| Moving Average: |
MA(5): 0.13 MA(20): 0.14
MA(100): 0.15 MA(250): 0.8 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 22.5 %D(3): 35.2 |
| RSI: |
RSI(14): 41.4  |
| 52-week: |
High: 3.39 Low: 0.09 |
| Average Vol(K): |
3-Month: 3,512 (K) 10-Days: 1,019 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ HGEN ] has closed above bottom band by 18.2%. Bollinger Bands are 45.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.14 - 0.14 |
0.14 - 0.14 |
|
Low:
|
0.13 - 0.13 |
0.13 - 0.13 |
|
Close:
|
0.14 - 0.14 |
0.14 - 0.14 |
|
Company Description |
|
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ‘cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey. |
Headline News |
Fri, 24 Mar 2023
Is Humanigen Inc (HGEN) Stock a Good Value Friday? - InvestorsObserver
Fri, 24 Mar 2023
North American Morning Briefing : Stock Futures -2- - Marketscreener.com
Wed, 22 Mar 2023
Humanigen Inc. (HGEN) Shares Down Despite Recent Market ... - The News Heater
Wed, 22 Mar 2023
Is Humanigen Inc. (NASDAQ: HGEN) Worth Your Money In 2023? - Marketing Sentinel
Fri, 17 Mar 2023
North American Morning Briefing : Focus on Bank -2- - Marketscreener.com
Thu, 02 Mar 2023
Is it Time to Dump Humanigen Inc (HGEN) Stock After it Has Fallen 6.25% in a Week? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
119 (M) |
|
% Held by Insiders
|
1.1013e+008 (%) |
|
% Held by Institutions
|
11.9 (%) |
|
Shares Short
|
5,780 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-3 |
|
Return on Assets (ttm)
|
151.5 |
|
Return on Equity (ttm)
|
-126.3 |
|
Qtrly Rev. Growth
|
3.33e+006 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0.04 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
-1.5 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-94 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0 |
|
Price to Sales
|
2.83 |
|
Price to Cash Flow
|
0.25 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
7.24e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2020-09-13 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
